residual gastric content after holding of glucagon-like peptide-1 receptor agonists before elective surgery

Conditions: Gastric Retention

Summary: glucagon-like peptide-1 agonists (glp-1ra) are a family of medications used for diabetes and weight loss. one of their effect is to slow down stomach emptying. the goal of this study is to evaluate the effect of glp-1ra on the effectiveness of fasting before a scheduled surgery. the question it aims to answer is: does this kind of medication increase the risk of having food or too much liquid in the stomach before a scheduled surgery, even if the minimum 6 hour fast is done? for this project, researchers will use gastric ultrasound to compare participants already taking one of these medications as part of their home treatment to participants who are not taking them. gastric ultrasound is a simple bedside exam using an echography machine that takes less than 5 minutes to do. participants will: -have a gastric ultrasound performed on them before their surgery

background: glucagon-like peptide-1 receptor agonists (glp-1ra) are glucose-lowering drugs that act through three mechanisms: stimulation of insulin secretion, inhibition of glucagon secretion and decrease of gastric emptying. the glp-1ra are now an important part of glycemic control in type 2 diabetes mellitus (t2dm). recently, glp-1 ra have received approval for weight loss, expanding their use in overweight or obese non-diabetic patients.the effect of glp-1ra on decreased gastric emptying has long been established but he clinical implication of this in the periprocedural setting is uncertain. recent guidelines recommend holding the weekly-dosed for at least a week before elective surgery. considering the extended half-lives of once-weekly glp-1ra (approximately 6 days for semaglutide and 5 days for dulaglutide), it is unclear if following those guidelines is sufficient to make sure patients are not at high risk of aspiration hypothesis: this study will compare ultrasound-assessed residual gastric content (rgc) between once-weekly glp-1ra users that stopped their medication for 7 days or more before elective surgery and patients not taking glp-1ra. the investigators hypothesized that even with appropriate holding of glp-1ra, those patients may have increased rgc and be at higher risk of aspiration. objectives: primary objective: • to investigate the relation between glp-1ra use and increased rgc secondary objectives: * to assess the relation between the number of days since the last dose of glp-1ra and increased rgc * to assess the relation between the dose of glp-1ra and rgc exploratory objectives: * to explore the relation between other known risk factors of gastroparesis and increased rgc * to explore the relation between the time since the last oral intake and increased rgc methods : a gastric ultrasound (gus)will be performed on all patients to assess rgc using a published validated and reproductible method used in recent trials. the acquisition of images will be performed by a blinded anesthesiologist or anesthesiology resident using a dedicated ultrasound machine. the images will be saved and reviewed by another blinded trained anesthesiologist. significance/importance: the results of this study could challenge the actual recommendations for glp-1ra stoppage before surgery and help improve perioperative care for patients taking glp-1ra.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) class 1-4 patients * age ≥ 18 years old * fasted state (2 hours for clear liquids, 6 hours for solids) * elective surgery * last dose of once-weekly semaglutide or dulaglutide 7 days or more before surgery (for glp-1ra group) exclusion criteria: * last dose of glp-1ra less than 7 days before surgery * inability to lay on the right-side for ultrasound * pregnancy * history of gastric surgery or large hiatal hernia

Keywords: glucagon-like peptide 1 gastric ultrasound surgery diabetes weight loss increased residual gastric content semaglutide dulaglutide